PIPE-307 demonstrated an acceptable safety and tolerability profile PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast letter acuity (LCLA) SAN DIEGO / Nov 20, 2025 / Business Wire / Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or...Read more
CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,...Read more
Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable...Read more
FDA Response Streamlines Path to Commercial Production of PF614 SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system...Read more
Following Priority Review, the U.S. FDA granted HYRNUO® (sevabertinib) approval for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by...Read more
EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance...Read more
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Regeneron Pharmaceuticals | 34.25 4.87 | $737.00 |
| Nutex Health | 30.15 26.87 | $142.34 |
| Exact Sciences | 14.44 16.76 | $100.62 |
| Abivax | 9.95 8.81 | $122.90 |
| PACS Group | 9.05 53.77 | $25.88 |
| Natera | 7.20 3.30 | $225.55 |
| Movano Health | 6.97 224.12 | $10.08 |
| Tyra Biosciences | 4.38 26.35 | $21.00 |
| Bolt Biotherapeutics | 4.24 758.68 | $4.80 |
| argenx | 3.91 0.43 | $918.50 |
| Olema Oncology | 2.58 13.28 | $22.01 |
| GE HealthCare | 2.44 3.37 | $74.75 |
| iRhythm Technologies | 2.40 1.43 | $169.70 |
| Waters | 2.37 0.63 | $378.62 |
| STERIS | 2.27 0.89 | $256.98 |
| UnitedHealth | 2.24 0.72 | $311.33 |
| Agios Pharmaceuticals | 2.23 9.98 | $24.57 |
| Solventum | 2.20 2.85 | $79.51 |
| Company | Volume | Last Trade |
|---|---|---|
| Mobile-health Network Solutions | 239,422,396 | $3.11 |
| Exact Sciences | 135,685,393 | $100.62 |
| Psyence Biomedical | 75,110,068 | $1.73 |
| Plus Therapeutics | 72,472,636 | $0.49 |
| Recursion | 59,508,228 | $3.85 |
| Applied Therapeutics | 53,404,804 | $0.28 |
| Pfizer | 50,550,442 | $24.40 |
| PacBio | 36,706,412 | $1.89 |
| Geron | 34,383,951 | $1.10 |
| Clearmind Medicine | 31,135,451 | $0.20 |
| Heron Therapeutics | 29,635,469 | $1.06 |
| InMed Pharmaceuticals | 29,121,524 | $1.24 |
| Olema Oncology | 27,044,195 | $22.01 |
| Humacyte | 26,515,071 | $1.12 |
| Moderna | 25,146,897 | $22.36 |
| ImmunityBio | 21,468,334 | $2.02 |
| Agios Pharmaceuticals | 20,961,226 | $24.57 |
| Nuvation Bio | 20,136,659 | $7.02 |
| Incannex Healthcare | 19,075,044 | $0.33 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
